FibroGen マネジメント

マネジメント基準チェック /24

FibroGenの CEO はThane Wettigで、 Jul2023年に任命され、の在任期間は 1.33年です。の年間総報酬は$ 3.64Mで、 15.7%給与と84.3%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.22%を直接所有しており、その価値は$ 86.25K 。経営陣と取締役会の平均在任期間はそれぞれ4年と5.9年です。

主要情報

Thane Wettig

最高経営責任者

US$3.6m

報酬総額

CEO給与比率	15.7%
CEO在任期間	1.3yrs
CEOの所有権	0.2%
経営陣の平均在職期間	4yrs
取締役会の平均在任期間	5.9yrs

経営陣の近況

Recent updates

Little Excitement Around FibroGen, Inc.'s (NASDAQ:FGEN) Revenues As Shares Take 26% Pounding

Oct 29

The Market Doesn't Like What It Sees From FibroGen, Inc.'s (NASDAQ:FGEN) Revenues Yet As Shares Tumble 65%

Aug 19

Little Excitement Around FibroGen, Inc.'s (NASDAQ:FGEN) Revenues As Shares Take 44% Pounding

Jul 04

FibroGen, Inc.'s (NASDAQ:FGEN) Share Price Boosted 35% But Its Business Prospects Need A Lift Too

Mar 22

There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 148% Share Price Rise

Feb 05

FibroGen, Inc. (NASDAQ:FGEN) Held Back By Insufficient Growth Even After Shares Climb 42%

Dec 22

A Look At The Intrinsic Value Of FibroGen, Inc. (NASDAQ:FGEN)

Nov 24

Revenues Not Telling The Story For FibroGen, Inc. (NASDAQ:FGEN)

Apr 18

Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?

Feb 13

The FibroGen, Inc. (NASDAQ:FGEN) Analysts Have Been Trimming Their Sales Forecasts

Nov 12

Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?

Oct 09

FibroGen completes patient enrollment for Roxadustat to treat anemia in patients

Aug 26

FibroGen Q2 2022 Earnings Preview

Aug 05

Is FibroGen (NASDAQ:FGEN) Using Debt Sensibly?

Jul 06

Is FibroGen (NASDAQ:FGEN) Using Debt Sensibly?

Mar 31

Time To Worry? Analysts Are Downgrading Their FibroGen, Inc. (NASDAQ:FGEN) Outlook

Mar 05

Is FibroGen (NASDAQ:FGEN) Using Debt In A Risky Way?

Dec 08

CEO報酬分析

FibroGen の収益と比較して、Thane Wettig の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$122m
Jun 30 2024	n/a	n/a	-US$168m
Mar 31 2024	n/a	n/a	-US$240m
Dec 31 2023	US$4m	US$573k	-US$284m
Sep 30 2023	n/a	n/a	-US$294m
Jun 30 2023	n/a	n/a	-US$322m
Mar 31 2023	n/a	n/a	-US$307m
Dec 31 2022	US$3m	US$535k	-US$294m
Sep 30 2022	n/a	n/a	-US$362m
Jun 30 2022	n/a	n/a	-US$220m
Mar 31 2022	n/a	n/a	-US$281m
Dec 31 2021	US$3m	US$510k	-US$290m
Sep 30 2021	n/a	n/a	-US$215m
Jun 30 2021	n/a	n/a	-US$231m
Mar 31 2021	n/a	n/a	-US$183m
Dec 31 2020	US$4m	US$263k	-US$189m

報酬と市場: Thaneの総報酬 ($USD 3.64M ) は、 US市場 ($USD 650.80K ) の同規模の企業の平均を上回っています。

報酬と収益: Thaneの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Thane Wettig (59 yo)

1.3yrs

在職期間

US$3,640,829

報酬

Mr. Thane Wettig serves as Director of FibroGen, Inc. since October 2, 2023. He serves as Chief Executive Officer at FibroGen, Inc. since October 2, 2023 and served as Interim Chief Executive Officer since...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Thane Wettig	CEO & Director	1.3yrs	US$3.64m	0.22% $ 86.2k
Juan Graham	Senior VP & CFO	3.2yrs	US$3.09m	0.082% $ 32.0k
Christine Chung	Senior Vice President of China Operations	17.8yrs	US$3.11m	0.30% $ 117.8k
Barry Berkowitz	Founder	29.8yrs	データなし	データなし
David DeLucia	Vice President of Corporate FP&A and Investor Relations	no data	データなし	データなし
Michael Lowenstein	Chief Legal Officer	8.6yrs	データなし	データなし
Tricia Stewart	Chief People Officer	3.5yrs	データなし	データなし
Kirk Christoffersen	Chief Business Officer	4yrs	データなし	データなし
Elizabeth Bearby	Senior VP of Regulatory	less than a year	データなし	データなし
Julian Stern	Secretary	31.8yrs	US$27.13k	データなし

4.0yrs

平均在職期間

56yo

平均年齢

経験豊富な経営陣: FGENの経営陣は経験豊富であると考えられます ( 4年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Thane Wettig	CEO & Director	1.1yrs	US$3.64m	0.22% $ 86.2k
George Martin	Chairman of Scientific Advisory Board	no data	データなし	データなし
Jeffrey Edwards	Independent Director	9.1yrs	US$385.53k	0.025% $ 9.9k
James Schoeneck	Independent Chairman of the Board	14.6yrs	US$499.58k	0.081% $ 31.6k
Maykin Ho	Independent Director	5.9yrs	US$375.53k	0.023% $ 9.0k
Aoife Brennan	Independent Director	4.3yrs	US$373.03k	0.020% $ 7.6k

5.9yrs

平均在職期間

63yo

平均年齢

経験豊富なボード: FGENの取締役会は経験豊富であると考えられます ( 5.9年の平均在任期間)。

FibroGen マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

CEO & Director recently bought US$95k worth of stock

FibroGen Appoints Deyaa Adib as Senior Vice President and Chief Medical Officer

FibroGen, Inc. Appoints Thane Wettig as Chief Executive Officer

Mark Eisner Resigns as Chief Medical Officer of Fibrogen, Inc., Effective September 8, 2023

Insufficient new directors

Fibrogen, Inc. Announces Chief Executive Officer Changes

Recent updates

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

FibroGen, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Little Excitement Around FibroGen, Inc.'s (NASDAQ:FGEN) Revenues As Shares Take 26% Pounding

FibroGen Receives Nasdaq Notification of Non-Compliance with Minimum Bid Price Requirement

The Market Doesn't Like What It Sees From FibroGen, Inc.'s (NASDAQ:FGEN) Revenues Yet As Shares Tumble 65%

New minor risk - Shareholder dilution

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

FibroGen, Inc. Announces Topline Results from Two Late-Stage Pamrevlumab Pancreatic Cancer Studies

Consensus estimates of losses per share improve by 17%

FibroGen, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Little Excitement Around FibroGen, Inc.'s (NASDAQ:FGEN) Revenues As Shares Take 44% Pounding

FibroGen, Inc.(NasdaqGS:FGEN) dropped from Russell 3000 Index

FibroGen: Two New In-Licensed Oncology Drugs To Carry It Forward

FibroGen, Inc. Announces FDA Clearance of Investigational New Drug Application for FG-3165, A Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors

Pamrevlumab And Roxadustat: Evaluating FibroGen's Future Amid Financial Strains

FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer at the 2024 American Society of Clinical Oncology Annual Meeting

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Benign Growth For FibroGen, Inc. (NASDAQ:FGEN) Underpins Stock's 28% Plummet

FibroGen, Inc. to Report Q1, 2024 Results on May 06, 2024

FibroGen, Inc. to Present Clinical Data from Dose Escalation Phase 1B Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer at 2024 American Society of Clinical Oncology Annual Meeting

Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals Announce Settlement with FibroGen, Inc

Fibrogen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

FibroGen, Inc.'s (NASDAQ:FGEN) Share Price Boosted 35% But Its Business Prospects Need A Lift Too

CEO & Director recently bought US$95k worth of stock

FibroGen Appoints Deyaa Adib as Senior Vice President and Chief Medical Officer

Full year 2023 earnings: EPS and revenues miss analyst expectations

FibroGen, Inc. to Report Q4, 2023 Results on Feb 26, 2024

There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 148% Share Price Rise

New major risk - Financial position

FibroGen, Inc. Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer

FibroGen, Inc. (NASDAQ:FGEN) Held Back By Insufficient Growth Even After Shares Climb 42%

Now 25% undervalued after recent price drop

A Look At The Intrinsic Value Of FibroGen, Inc. (NASDAQ:FGEN)

Now 30% undervalued after recent price drop

New minor risk - Financial position

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

FibroGen, Inc. Receives Non-Compliance Letter from Nasdaq Related to Minimum Bid Price

FibroGen, Inc. Receives Non-Compliance Letter from Nasdaq Related to Minimum Bid Price

FibroGen, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Price target decreased by 17% to US$10.38

FibroGen, Inc. Appoints Thane Wettig as Chief Executive Officer

Mark Eisner Resigns as Chief Medical Officer of Fibrogen, Inc., Effective September 8, 2023

Insufficient new directors

Fibrogen, Inc. Announces Topline Results from Lelantos-2, A Phase 3 Clinical Study of Pamrevlumab in Ambulatory Muscular Dystrophy

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Fibrogen, Inc. Announces Chief Executive Officer Changes

FibroGen, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Consensus revenue estimates decrease by 13%, EPS upgraded

Price target decreased by 25% to US$19.00

Now 81% undervalued after recent price drop

Insider notifies of intention to sell stock

FibroGen, Inc. Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy

FibroGen, Inc. Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia

Consensus EPS estimates fall by 20%, revenue upgraded

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Revenues Not Telling The Story For FibroGen, Inc. (NASDAQ:FGEN)

Insider recently sold US$124k worth of stock

CEO & Director recently sold US$1.2m worth of stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target increased by 16% to US$24.83

FibroGen, Inc. to Report Q4, 2022 Results on Feb 27, 2023

Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?

Price target increased by 21% to US$21.33

Price target increased to US$17.60

Chief Financial Officer notifies of intention to sell stock

Now 20% undervalued

Price target increased to US$16.40

The FibroGen, Inc. (NASDAQ:FGEN) Analysts Have Been Trimming Their Sales Forecasts

Price target increased to US$16.40

マネジメント基準チェック /24